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We have previously discovered a synergistically therapeutic combination of two Toll-like
receptor ligands, an oligodeoxynucleotide (ODN) and Pam2CSK4. Aerosolization of these
ligands stimulates innate immunity within the lungs to prevent pneumonia from bacterial
and viral pathogens. Here we examined the safety and tolerability of this treatment in
mice, and characterized the expression of biomarkers of innate immune activation. We
found that neutrophils appeared in lung lavage ﬂuid 4 h after treatment, reached a peak
at 48 h, and resolved by 7 days. The peak of neutrophil inﬂux was accompanied by a
small increase in lung permeability. Despite the abundance of neutrophils in lung lavage
ﬂuid, only rare neutrophils were visible histopathologically in the interstitium surrounding
bronchi and veins and none were visible in alveolar airspaces. The cytokines interleukin 6
(IL-6), tumour necrosis factor, and Chemokine (C-X-C motif) ligand 2 rose several hundred-
fold in lung lavage ﬂuid 4 h after treatment in a dose-dependent and synergistic manner,
providing useful biomarkers of lung activation. IL-6 rose ﬁvefold in serum with delayed
kinetics compared to its rise in lavage ﬂuid, and might serve as a systemic biomarker of
immune activation of the lungs. The dose–response relationship of lavage ﬂuid cytokines
was preserved in mice that underwent myeloablative treatment with cytosine arabinoside
to model the treatment of hematologic malignancy. There were no overt signs of distress
in mice treated with ODN/Pam2CSK4 in doses up to eightfold the therapeutic dose, and
no changes in temperature, respiratory rate, or behavioral signs of sickness including sugar
water preference, food disappearance, cage exploration or social interaction, though there
was a small degree of transient weight loss.We conclude that treatment with aerosolized
ODN/Pam2CSK4 is well tolerated in mice, and that innate immune activation of the lungs
can be monitored by the measurement of inﬂammatory cytokines in lung lavage ﬂuid and
serum.
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INTRODUCTION
Infectious pneumonia exacts a high burden of morbidity andmor-
tality worldwide (Mizgerd, 2008; Lozano et al., 2012). Efforts to
protect populations from pneumonia have focused historically
on antibiotics and vaccine-enhanced adaptive immunity. Using
aerosolized bacterial lysates, we found that innate defenses of
the lungs of mice can be stimulated therapeutically to induce
a high level of resistance to microbial infection (Clement et al.,
Abbreviations: i.p., intraperitoneally; i.v., intravenously; LPS, lipopolysaccha-
ride; ODN, oligodeoxynucleotide; ODN M362, TCG TCG TCG TTC GAA CGA
CGT TGA T; O/P, ODN M362 and Pam2CSK4 at a 1:4 molar ratio; Pam2CSK4,
2,3-bis(palmitoyloxy)-2-propyl-Cys-Ser-Lys-Lys-Lys-Lys-OH; qRT-PCR, quantita-
tive reverse transcription-polymerase chain reaction; SAA1, serum amyloid A1;
TLR, Toll-like receptor.
2008; Tuvim et al., 2009; Evans et al., 2010a,b). Resistance to
infection rose rapidly after stimulation, reached a maximum by
4 h, remained at a high level for several days, and then slowly
declined to baseline after several more days. Resistance to infec-
tionwas accompanied by transient inﬂammationwithin the lungs,
including an inﬂux of neutrophils and cytokines into lavage ﬂuid
(Clement et al., 2008; Tuvim et al., 2009). However treatment
appeared to be well tolerated with no apparent adverse behavioral
effects, only a minimal rise of cytokines in serum, and resolution
of lung inﬂammation within a week (Clement et al., 2008; Tuvim
et al., 2009).
Subsequently, we found that genetic deletion of the innate
immune adaptor MyD88 resulted in a complete loss of inducible
resistance in response to aerosolized bacterial lysates (Duggan
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et al., 2011). This suggested that a subset of Toll-like recep-
tor (TLR) ligands played a dominant role in the induction of
resistance.We screened synthetic TLR ligands and found that even
though no single aerosolized ligand was capable of inducing a
high level of resistance, a combination of two particular ligands
induced a high level of resistance to bacterial and viral infection
of the lungs (Duggan et al., 2011; Tuvim et al., 2012; Cleaver et al.,
2014). This combination consisted of a Class C oligodeoxynu-
cleotide (ODN), which is a ligand for the TLR9 homodimer, and
Pam2CSK4, which is a ligand for the TLR2/6 heterodimer. The
concentration and ratio of the two components were then sys-
tematically varied to identify an optimal therapeutic formulation
(Evans et al., 2011), which was found to be 1 μM ODN and 4 μM
Pam2CSK4 (together designated O/P) in a nebulized solution of
4ml. This aerosol therapy is being considered for clinical studies of
its safety and efﬁcacy in protecting immunocompromised subjects
against opportunistic lung infections and normal subjects against
virulent emerging and bioterror pathogens. Here we report the
results of studies in mice to determine the safety and tolerabil-
ity of aerosolized O/P and to identify biomarkers of lung innate
immune activation that could help guide dosing in clinical trials.
MATERIALS AND METHODS
ANIMALS AND REAGENTS
All mice were handled in accordance with the policies of the
Institutional Animal Care and Use Committee of The University
of Texas MD Anderson Cancer Center. Adult (5–8 weeks old)
male and female Swiss Webster (SW) and C57BL/6 mice (all from
Charles River) were used. Mice were housed in plastic cages up
to 5 per cage with ¼ inch Anderson Bed-O-Cob bedding (Lab
Supply) on a 12 h light/dark cycle (7 am to 7 pm) with access
to Regular Purina Rodent Diet 5001 (Lab Supply) and water ad
libitum except as noted for behavioral studies. Where applicable,
mice were euthanized by exsanguination under deep anesthesia
with 2,2,2-tribromoethanol (Avertin, 500 mg/kg body weight)
injected intraperitoneally (i.p.). All reagents were obtained from
Sigma-Aldrich, except as indicated.
AEROSOL TREATMENTS
Oligodeoxynucleotide 5′ TCG TCG TCG TTC GAA CGA CGT
TGA T 3′ as the sodium salt on a nuclease-resistant phospho-
rothioate backbone (ODN M362) was purchased from TriLink
BioTechnologies, and 2,3-bis(palmitoyloxy)-2-propyl-Cys-Ser-
Lys-Lys-Lys-Lys-OH (Pam2CSK4) as the triﬂuoroacetic acid salt
was purchased from Bachem. To treat the animals, ODN and
Pam2CSK4 in indicated amountswere separately dissolved in 3mL
of endotoxin-free sterile water and then combined and placed in
an Aerotech II nebulizer (Biodex Medical Systems). The nebu-
lizer was driven by 10 L/min of air supplemented with 5% CO2
to promote deep breathing, and was connected by polyethylene
tubing (30 cm × 22 mm) to a 10 L polyethylene exposure cham-
ber that was vented to a biosafety hood. Mice were exposed to
the aerosols for 20 min, resulting in the nebulization of approxi-
mately 4 ml of O/P solution. Control mice (prior to treatment for
kinetic experiments and no O/P for dose–response experiments)
were exposed to aerosols of water alone for 20min. For estimation
of the amount of O/P deposited within the lungs of mice in the
aerosol chamber, we used Guyton’s formula predicting deposition
of 0.2% of a delivered aerosol (Bide et al., 2000), together with our
own measurement of 0.05% using aerosolized solutions of Evans
Blue, to estimate aerosol deposition at 0.1%.
LUNG LAVAGE FLUID AND SERUM ANALYSES
Lung lavage ﬂuid was obtained by instilling, collecting and com-
bining two aliquots of 1 mL each of PBS through a 20 gauge
Luer stub adapter cannula (BD Biosciences) inserted through
rings of the exposed trachea of anesthetized animals at the indi-
cated time points. Total leukocyte count was determined using
a hemocytometer (Hausser Scientiﬁc), and differential count by
cytocentrifugation (CytoSpin 4, Thermo Fischer Scientiﬁc) of
300 μL of lavage ﬂuid at 300 × g for 5 min followed by Wright-
Giemsa staining. For cytokine analysis, the remaining lavage
ﬂuid was centrifuged at 1000 × g for 10 min and the cell-free
supernatant collected and frozen. For serum cytokine measure-
ment, blood was obtained from anesthetized mice by cardiac
puncture and allowed to coagulate, then centrifuged and frozen.
Cytokine concentrations in lavage ﬂuid and serum were measured
in duplicate bymultiplexed sandwich enzyme-linked immunosor-
bent assay (ELISA) using SearchLight Array Services (Aushon
Biosystems).
HISTOLOGIC ANALYSES
Lungs were inﬂated at 15 cm H2O pressure with 10% buffered
formalin and ﬁxed in situ for 5 min at room temperature, then
removed from the thoracic cavity and ﬁxed overnight at 4 ◦C.
Fixed lungs were embedded in parafﬁn and cut into 5μm sections
and placed on glass slides. Sections were dewaxed and rehydrated,
and tissueswere stainedwithHarris’hematoxylin and eosin (H&E)
to examine cellular elements, Masson’s trichrome (MTC) stain or
picrosirius red (PSR) to examine collagen, and periodic acid ﬂu-
orescent Schiff ’s reagent (PAFS) to examine mucin accumulation
as described (Moghaddam et al., 2008).
MYELOABLATION AND INFECTIOUS CHALLENGE
Micewere injected i.p. four times (days−8,−5,−3,−1)with cyto-
sine arabinoside, 100 mg/kg body weight, as described (Clement
et al., 2008). On day 0,micewere challengedwith aerosolized Pseu-
domonas aeruginosa targeted to LD80–LD100 as described (Duggan
et al., 2011). Mice were examined twice daily by veterinarians
blinded to their treatments and euthanized if found distressed or
removed from their cages if found dead. The numbers of surviving
mice were counted daily by investigators.
LUNG PERMEABILITY ASSESSMENT
Lung permeability was measured three ways – total protein in
lung lavage ﬂuid, the amount of systemically administered dye
in lung lavage ﬂuid, and total lung weight. The protein concen-
tration of lavage ﬂuid was measured using a BCA Protein Assay
Kit (Thermo Fischer Scientiﬁc) according to the manufacturer’s
instructions. Tomeasuredye translocation, anesthetizedmicewere
injected intravenously (i.v.) in the tail vein with 100μl Evans Blue
dye (30 mM) in PBS with 0.1% bovine serum albumin, and the
amount of dye appearing in lavage ﬂuid was measured with a
spectrophotometer at 620 nm. For a positive control, mice were
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given 3.7 mg of oleic acid combined with the dye injection. Wet
lung weight was measured using mice that did not undergo lung
lavage.
EXPRESSION OF SAA1 IN LIVER BY QUANTITATIVE PCR
Serum amyloid A1 (SAA1) mRNA expression in the livers
of challenged mice was measured using quantitative reverse
transcription-polymerase chain reaction (qRT-PCR). Excised liv-
ers were snap frozen in liquid nitrogen, homogenized in TRIzol
reagent (Life Technologies) using a Bullet Blender (NextAdvance),
and total RNA was isolated as described in the TRIzol protocol.
Total RNA was further puriﬁed using the RNeasy kit (Qiagen).
qRT-PCR was performed using either the CFX96 Real-Time
System (Bio-Rad) or the StepOnePlus Real-Time PCR System
(Applied Biosystem) in conjunction with the TaqMan RNA-to-CT
1-step kit. Primer and probe sequenceswere the same as those used
previously (Quinton et al., 2009), and were purchased from Inte-
gratedDNATechnologies. Resultswere expressed as fold induction
normalized to the content of 18s rRNA as described (Jones et al.,
2006).
PHYSIOLOGIC AND BEHAVIORAL ASSESSMENTS
Mice were weighed at the indicated time points after challenge
using a laboratory scale, temperature was taken with a rectal ther-
mometer (Sper Scientiﬁc, Cat # 800060), and respiratory rate was
measured using a plethysmograph (Scireq) with mice monitored
in the chamber for 2 min. Sickness in mice can be measured by
decreases in sucrose preference, food intake, locomotor activity,
and social exploration (O’Connor et al., 2009). A sucrose anhedo-
nia test was conducted as described (Willner et al., 1992). Brieﬂy,
ﬁve male SW mice were housed in each cage in the presence of
two water bottles, one containing only water and the other con-
taining sucrose (1% w/v) in water. The placement of the bottles
was alternated daily. Mice were acclimated for 1 week prior to an
experiment lasting 4 days. Sucrose preference was calculated by
dividing the amount of sucrose solution consumed by the total
liquid consumed. Escherichia coli endotoxin was used as a pos-
itive control (50 μg/mouse i.p.). Food consumption, locomotor
activity and social exploration were also measured as behavioral
indices of distress as described (Kent et al., 1992; Mormede et al.,
2004; O’Connor et al., 2009). For these studies mice were housed
singly in standard shoebox cages with Harlan/Teklad Laboratory
Grade Sani-Chips bedding in a temperature (23◦C) and humidity
(45–55%) controlled environment with a 12/12-h modiﬁed dark–
light cycle (lights on at 10:00 pm). Aerosol treatments and i.p.
injections were given at the beginning of the dark period at 10:00
am. Behaviorwas assessedduring thedark cycle in thepresence of a
darkroom red light by observers blinded to the mouse treatments.
The mice were fed irradiated Prolab Isopro RMH 3000 (LabDiet).
Food and water were freely available and mice were handled for
1 week prior to experimentation. For a positive control of all the
behavioral indices besides sucrose preference, mice were injected
with a lower dose of E. coli endotoxin (20 μg/mouse i.p.). Food
consumption was measured by weighing remaining food pellets at
intervals during a 24 h period. Locomotor activity was assessed by
placing mice into a new cage similar to the home cage but devoid
of bedding. The cage was divided into four virtual quadrants, and
the number of line crossings (“quadrant entries”) and rearing on
hind legs (“rears”) were counted over a 5-min period. Social inter-
action was assessed immediately after the 6 and 24 h locomotor
activity assessments by placing into the cage a novel mouse of
the same sex and age that had not been treated with an aerosol
or i.p. injection. Time spent interacting was scored over a 5-min
period when the resident mouse initiated nose-to-nose interac-
tion, anogenital snifﬁng, or climbing over or under the novel
mouse.
STATISTICAL METHODS
In all studies except those of histopathology, descriptive statis-
tics were used to summarize the percentage change of mean values
from controls. In all ﬁgures, error bars represent the standard error
of the mean. For studies of lung lavage ﬂuid and serum cytokine
and cellular responses and hepatic SAA1 transcript responses,
unpaired t-test was used to assess statistically signiﬁcant changes
from baseline with a two-sided signiﬁcance level of 0.05. For anal-
ysis of synergistic interactions between ODN and Pam2CSK in
the induction of lung lavage ﬂuid cytokine responses, a two-factor
ANOVA model was used with an interaction term. For mouse
survival studies, Fisher’s exact test was used to assess statistically
signiﬁcant changes from untreated controls with a two-sided sig-
niﬁcance level of 0.05. For mouse weight and temperature studies,
paired t-test was used to assess statistically signiﬁcant changes
from vehicle treated controls with a two-sided signiﬁcance level
of 0.05 at each time point; mixed effects regression methods
were used to model the percentage change from baseline as a
function of dose, study day, and the interaction between dose
and study day. Food consumption, locomotor activity and social
exploration were assessed using one-way repeated measures of
ANOVA. Post hoc analyses were conducted using Fisher’s protected
least signiﬁcant difference. For all studies, animals were randomly
assigned to treatment groups, and investigators conducting assess-
ments of mice or harvested samples were blinded to treatments.
All ﬁgures show a representative experiment that was performed
at least two times except for measurement of lung lavage ﬂuid
cytokine responses in myeloablated mice, which was only per-
formed once because of the distress to mice treated with cytotoxic
chemotherapy.
RESULTS
KINETICS OF LUNG INFLAMMATION AFTER A SINGLE O/P EXPOSURE
To assess the onset and duration of lung inﬂammation resulting
froma single exposure to 4ml of aerosolized 1μMODNand 4μM
Pam2CSK4 (hereafter, “1×” O/P), we measured cytokines and
leukocytes in lung lavage ﬂuid. Tumour necrosis factor (TNF) and
chemokine (C-X-C motif) ligand 2 (CXCL2) increased 234-fold
and 286-fold frombaseline, respectively,with both cytokines peak-
ing 2 h after treatment (Figure 1A). IL-6 peaked later, at 8 h, and
increased 285-fold. Concentrations of all three cytokines returned
to their low baseline levels 48 h after treatment. Neutrophil levels
rose more slowly than cytokine levels, with no signiﬁcant increase
measureable at 2 h (Figure 1B). However there was a marked
inﬂux of neutrophils at 4 h, which peaked at 48 h, then declined
at 72 h, with complete resolution at 7 days (168 h). In contrast,
macrophages initially declined with a nadir at 24 h, then increased
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FIGURE 1 |Time-course of lung inflammatory responses to aerosolized
O/P. (A,B) Mice were exposed to a single aerosolized 1× dose of O/P,
then sacriﬁced at the indicated times, and cytokine concentrations were
measured in the supernatants (A) and macrophage and neutrophil
numbers were measured in the cell pellets (B) of lung lavage ﬂuid.
Cytokine levels differed from baseline for IL-6 at 2, 4, and 8 h, for CXCL2
at 2, 4, 8, 24 h, and for TNF at 2, 4, 24, 48 h (A). Leukocyte levels
differed from baseline for macrophage at 96, 168, 672 h, and for
neutrophils at 4, 8, 24, 48, 72 h (B). (C,D) Mice were exposed twice
weekly for 3 weeks to aerosolized 1× doses of O/P, then sacriﬁced at the
indicated times after the last dose, and cytokine concentrations were
measured in the supernatants (C) and macrophage and neutrophil
numbers were measured in the cell pellets (D) of lung lavage ﬂuid. All
three cytokines levels differed from baseline at 4 h (C). Macrophage
levels differed from baseline only at 72 h, and neutrophil levels did not
differ from baseline at any time (D). (n = 3–4 for all experiments).
to a peak at 4–7 days (Figure 1B). Eosinophils were not observed
at any time, but small numbers of lymphocytes (generally < 3%
of total leukocytes) were observed from 2 to 7 days (not shown).
KINETICS OF LUNG INFLAMMATION AFTER MULTIPLE O/P EXPOSURES
We then examined lung inﬂammation in response to repetitive
exposure to aerosolized O/P given twice weekly for 3 weeks to
mimic a prophylactic therapeutic regimen. The cytokine response
4 h after the last of six aerosol exposures (Figure 1C) was blunted
as compared to the response 4 h after a single exposure (0.9
vs 2.7 ng/mL for IL-6, 0.6 vs 3.1 ng/mL for CXCL2, 0.03 vs
0.3 ng/mL for TNF). Remarkably, lung lavage ﬂuid neutrophil
levels (Figure 1D) barely rose at all at any time after six expo-
sures. Lavage ﬂuid macrophage levels rose 4 h after six exposures
(Figure 1D), in contrast to the response to a single exposure
(Figure 1B). They remained elevated for 3 weeks (504 h) before
returning to baseline after 4 weeks (672 h).
DOSE–RESPONSE RELATIONSHIPS BETWEEN LUNG INFLAMMATION
AND O/P EXPOSURE
We next determined the dose–response relationship between O/P
exposure and lung inﬂammatory responses across a 64-fold range
of doubling concentrations (1/8×–8×) centered around the ther-
apeutic 1× concentration. The highest concentration was 8×
because a precipitate formed at higher concentrations. Lung lavage
ﬂuid neutrophil levels 24 h after O/P exposure showed a posi-
tively correlated sigmoidal dose–response curve, but macrophages
showed a reciprocal response (Figure 2A). The plateau lev-
els of the neutrophil and macrophage responses to the higher
concentrations of O/P were reached by 2× O/P, and for com-
parison a representative efﬁcacy (mouse survival) dose–response
curve is also illustrated (Figure 2A). Cytokine levels were mea-
sured 4 h after treatment, a time point intermediate between
the peak of TNF and CXCL2 at 2 h and the peak of IL-6
at 8 h. All three cytokines demonstrated saturable, sigmoidal
dose–response curves (Figure 2B). The EC50 values of these
responses are listed in Table 1, together with the more clini-
cally relevant EC90 values. Importantly, the upper inﬂection point
(EC90) of the dose–response curve for each cytokine (Figure 2B
and Table 1) fell within one doubling concentration of the 1×
therapeutic dose (Figure 2A, Table 1, and Evans et al., 2011),
indicating that the cytokine dose–response relationships corre-
late with the resistance dose–response relationship (Duggan et al.,
2011; Evans et al., 2011). Since ODN and Pam2CSK4 interacted
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FIGURE 2 | Dose–response of lung inflammation to aerosolized O/P.
(A,B) Mice were exposed to increasing concentrations of O/P as indicated,
then sacriﬁced after 24 h to measure macrophage and neutrophil numbers
(A) or after 4 h to measure cytokine levels (B). For comparison, the survival
of mice exposed to increasing concentrations of O/P from challenge 24 h
later with aerosolized P. aeruginosa is illustrated (A). Neutrophil levels
differed from baseline at concentrations ≥1/4×, survival levels at
concentrations ≥1/2×, macrophage levels at concentrations ≥1×, and
levels of all three cytokines at all concentrations. (C) Mice were exposed to
aerosolized 1× ODN alone, Pam2 alone, or ODN and Pam2 together, and
cytokine levels in lung lavage ﬂuid were measured 4 h later. Levels of all
cytokines differed from baseline in response to all treatments except IL-6 in
response to ODN alone, and the levels of IL-6 (p = 0.012) andTNF
(p = 0.025) but not CXCL2 (p = 0.185) in response to ODN and Pam2
together were more than additive for responses to ODN alone and Pam2
alone. (n = 3–4 for all experiments).
Table 1 | Dose–response relationships of O/P.
Response EC50 EC90
Normal mice
Host survival 0.42 1.02
Lavage neutrophil rise 0.74 1.38








Values for the concentration of O/P, expressed as a fraction of 1× O/P (1 μM ODN
M362 and 4 μM Pam2CSK4), resulting in 50% (EC50) and 90% (EC90) maximal
host responses.
synergistically to induce resistance to infection (Duggan et al.,
2011; Evans et al., 2011), we tested whether they also interact syn-
ergistically to induce cytokine expression. ODN alone induced
only very low levels of cytokines whereas Pam2CSK4 induced
robust levels of IL-6, CXCL2, and TNF (Figure 2C), similar to
their respective abilities to elicit neutrophil inﬂux into lung lavage
ﬂuid (Duggan et al., 2011). Together, they synergistically increased
cytokine levels (Figure 2C).
LUNG HISTOPATHOLOGY AFTER O/P EXPOSURE
Lung inﬂammation after aerosol O/P administration was also
assessed histopathologically. Despite the inﬂux of neutrophils into
lavage ﬂuid (Figures 1B and 2A), no neutrophil inﬁltration into
alveoli was perceptible on histologic analysis at any time point
after a single exposure to O/P (Figure 3A). Small numbers of neu-
trophils were visible in the interstitial tissue of bronchovascular
bundles from 4 to 72 h. In contrast, infection with Streptococ-
cus pneumoniae as a positive control caused intense neutrophilic
inﬁltration of interstitial tissue and alveoli at 24 h (Figure 3A),
consistent with the more than 10-fold greater number of neu-
trophils in lung lavage ﬂuid in this infection model than with
O/P (not shown). The lungs of mice were also examined weekly
for 4 weeks beginning 1 week after the last of six exposures to
O/P given twice weekly for 3 weeks. No inﬂammatory cell inﬁl-
tration of the lungs was apparent 1 week or later after repetitive
O/P exposure (Figure 3B). Lung tissues were also examined for
evidence of ﬁbrosis using MTC and PSR stains, and ﬁbrosis was
not observed (not shown). Mucous metaplasia was not observed
by PAFS staining or epithelial injury by H&E staining in single or
multiple exposure experiments (not shown).
ANTIMICROBIAL RESISTANCE AND BIOMARKERS IN MYELOABLATED
MICE
Aerosolized O/P might be used to treat patients with acute
leukemia undergoing induction of remission therapy because
of their high susceptibility to pneumonia as a result of
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FIGURE 3 | Histopathology of mouse lungs in response to
aerosolized O/P. (A) Mice were exposed to a single aerosolized 1×
dose of O/P, then sacriﬁced at the indicated times. Their lungs were
ﬁxed, embedded, and sectioned, then stained with H&E. For
comparison, the lungs of a mouse sacriﬁced 24 h after challenge with
aerosolized S. pneumoniae are illustrated. (B) Mice were exposed twice
weekly for 3 weeks to aerosolized 1× doses of O/P, then sacriﬁced at
the indicated times after the last dose, and their lungs were ﬁxed,
embedded, and sectioned, then stained with H&E. (n = 3–4 for all
experiments).
myelosuppression from both the leukemia and its treatment
(Barreda et al., 2013). At a time when neutrophils are not available
to participate in pathogen defense, we hypothesize that stimula-
tion of the lung epithelium with aerosolized O/P could provide
transient resistance to infection. To test this hypothesis, we used
a mouse model of myeloablation with the antimetabolite cyto-
sine arabinoside that is commonly used to treat hematologic
malignancies. In this mouse model, no neutrophils are mea-
sureable in lung lavage ﬂuid after exposure to an aerosolized
bacterial lysate (Clement et al., 2008). Most mice treated with a
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single 1× dose of aerosolized O/P survived an otherwise lethal
challenge with P. aeruginosa 24 h later, with no apparent dif-
ference in protection between control mice and those treated
with cytosine arabinoside (Figure 4A). Aerosolized O/P also
induced a dose-dependent increase in lung lavage cytokines in
these mice (Figure 4B), similar to that observed in mice not
treated with cytosine arabinoside (Figure 2B). Together, these
results suggest that lung epithelial antimicrobial and inﬂamma-
tory responses are preserved despite treatment with myeloablative
chemotherapy.
LUNG PERMEABILITY AFTER O/P EXPOSURE
Treatment of leukemia can cause an increase in lung permeabil-
ity leading to impaired gas exchange as a result of inﬂammation
from tumor cell lysis and direct drug-induced lung injury (Tryka
et al., 1982; Briasoulis and Pavlidis, 2001). We evaluated the
effects of aerosolized O/P treatment on lung permeability to
help determine whether it might aggravate the increase in lung
permeability caused by tumor treatment. Initially we examined
the time course of changes in lung permeability by measuring
protein concentration in lung lavage ﬂuid, and found a small
transient increase 48 h after exposure to 1× aerosolized O/P
(Figure 5A; 0 at 4 h, 3% at 8 h, 46% at 24 h, 75% at 48 h,
36% at 72 h, −17% at 96 h). This increase in lung permeabil-
ity was also observed by measuring wet lung weight (Figure 5B).
Next we examined the dose–response relationship 48 h after O/P
aerosolization by measurement of both Evans Blue extravasation
and protein concentration in lung lavage ﬂuid (Figure 5C, left
side). There appeared to be a small increase in protein concen-
tration (40% for 1× and 60% for 8× O/P) as was observed in
the kinetic experiment, but it was not statistically signiﬁcant due
to the multiple comparisons. There was no increase in Evans
Blue extravasation, and no apparent respiratory distress in mice.
For comparison, we injected oleic acid i.v. (Figure 5C, right
side), which is a well-established model of increased permeability
due to lung injury (Wang et al., 2008). Oleic acid caused much
greater increases in Evans Blue extravasation (850%) and pro-
tein concentration (392%) in lung lavage ﬂuid than any dose
of aerosolized O/P, and caused obvious respiratory distress. We
also injected O/P i.v. to assess whether the permeability changes
induced by aerosolizedO/P are due to topical inﬂammationwithin
the lungs or to systemic inﬂammation from O/P that might
translocate into the circulation. Injection of up to 103-fold the
amount of O/P we calculate is deposited in the lungs by a 1×
aerosol (1 μm ODN and 4 μm Pam2 × 4 ml × 0.1% deposi-
tion = 4 pmol ODN and 16 pmol Pam2CSK4) did not result
in a measureable increase in Evans Blue extravasation or pro-
tein concentration or in apparent respiratory distress (Figure 8C).
Together, these results suggest that aerosolized O/P induces a mild
increase in lung permeability due to topical rather than systemic
inﬂammation.
SYSTEMIC CYTOKINES AFTER O/P EXPOSURE
There was no signiﬁcant increase in serum TNF or CXCL2 levels
above baseline measured 4 h after exposure to aerosolized O/P at
any concentration up to 8× (not shown). Serum IL-6 rose ﬁvefold
after exposure to 2× O/P, but this level did not further increase
with exposure to 4× or 8× O/P (Figure 6A). The kinetics of the
rise in serum IL-6 were delayed in comparison to the rise in lavage
ﬂuid IL-6, with the peak serum level occurring at 48 h (Figure 6B)
compared to the peak lavage ﬂuid level at 8 h (Figure 1A). The
low levels of serum cytokines in response to aerosolized O/P are
similar to what we previously observed with aerosolized bacterial
lysates (Clement et al., 2008; Tuvim et al., 2009), conﬁrming that
inﬂammation resulting from topical activation of innate immu-
nity within the lungs remains mostly conﬁned within the lungs.
Nonetheless, IL-6 might serve as a systemic biomarker of lung
epithelial activation.
HEPATIC SAA1 TRANSCRIPTS AFTER O/P EXPOSURE
As a sensitive index of systemic inﬂammation, we measured the
expression of transcripts of the acute phase reactant SAA1 in
FIGURE 4 | Protection from Pseudomonas pneumonia and expression of
biomarkers in myeloablated mice treated with aerosolized O/P. (A) Mice
were (black symbols) or were not (gray symbols) given four intraperitoneal
injections of cytosine arabinoside (AraC) over 8 days to ablate neutrophils.
Mice from both groups were then treated (circles) or not (squares) with a 1×
dose of aerosolized O/P, then challenged 24 h later with aerosolized P.
aeruginosa. Survival of mice treated with O/P differed from survival of
untreated mice regardless of whether they received AraC (n = 10). (B) Mice
myeloablated with cytosine arabinoside were exposed to increasing
concentrations of O/P as indicated, then sacriﬁced after 4 h for the
measurement of cytokine concentrations in lung lavage ﬂuid. Levels of all
cytokines differed from baseline in response to all treatments (n = 4).
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FIGURE 5 | Lung permeability changes in response to aerosolized O/P.
(A,B) Mice were exposed to a single 1× dose of aerosolized O/P, then
sacriﬁced at the indicated times to measure protein concentration in
lung lavage ﬂuid (A) or lung weight (B). Asterisks indicate differences in
comparison to mice treated with vehicle alone (n = 4 in A, 3 in B). (C)
Mice on the left were exposed to increasing concentrations of
aerosolized O/P as indicated, and those on the right were injected
intravenously with amounts of O/P estimated to be 1, 10, 100, or
1,000-fold the amount deposited in the lungs after a single aerosolized
1× dose. All mice were injected intravenously with Evans blue dye at
the time of exposure to aerosolized or intravenous O/P, then sacriﬁced
after 48 h for measurement of the concentration of protein and Evans
blue dye in lung lavage ﬂuid. For comparison, mice were injected with
oleic acid intravenously to induce a substantial increase in lung
permeability. Asterisks indicate differences in comparison to mice treated
with vehicle alone (n = 4).
liver (Quinton et al., 2009). Following the delivery of increasing
amounts of O/P, there was a small dose-dependent increase in
SAA1 mRNA expression in livers taken 4 h after the aerosoliza-
tion (Figure 6C). Similar to the kinetics of the rise in serum IL-6,
the peak level of SAA1 transcripts in the liver occurred between
24 and 48 h (Figure 6D, gray line). To assess whether the hep-
atic expression of SAA1 was due to translocation of aerosolized
O/P into the systemic circulation or to systemic transmission of
the local lung inﬂammatory response, we injected into the tail
vein the amount of O/P (4 pmol ODN and 16 pmol Pam2CSK4)
we estimated is deposited within the lungs of a mouse after
aerosolization of 1× O/P. This did not result in a measurable
increase in SAA1 transcripts in the liver (not shown). As a pos-
itive control, we injected 100-fold the amount of O/P deposited
by a 1× aerosol, which induced a higher and more rapid rise
in liver SAA1 transcript levels than aerosolization of 8× O/P
(Figure 6D, black line). Mice did not show behavioral signs
of distress in response to the tail vein injection of 100× O/P.
Together, these results suggest that themild hepatic SAA1 response
to aerosolizedO/P is due to systemic transmission of the local lung
inﬂammatory reaction rather than to translocation of O/P into the
circulation, and that this mild systemic inﬂammatory response is
subclinical.
ANIMAL PHYSIOLOGY AFTER O/P EXPOSURE
Animal weight, temperature and respiratory rate were measured
following O/P administration. There was a small (2–5%) decrease
in weight in all mice from 2 to 24 h after aerosol exposure
(Figure 7A), including those treated only with aerosolized water
(vehicle), that we attributed to the stress of handling and the fact
that mice huddle in a group and do not drink or eat during
nebulization. No O/P aerosol treatment group showed a sig-
niﬁcant decrease in weight compared to the group treated with
aerosolized water except the 8× O/P aerosol group that showed
a 7% decrease. There was a similar small decrease in tempera-
ture in all aerosol treatment groups, including mice treated with
water alone, but there were no signiﬁcant further decreases in any
group treated with aerosolized O/P as compared to mice treated
with water alone (Figure 7B). There were no signiﬁcant differ-
ences in respiratory rate for mice treated with therapeutic (1×) or
high (8×) concentrations of aerosolized O/P as compared to mice
treated with aerosolized water (Figure 7C). Together these results
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FIGURE 6 | Systemic inflammatory responses to aerosolized O/P.
(A) Mice were exposed to increasing concentrations of O/P as indicated, then
sacriﬁced after 4 h to measure cytokine levels in serum. IL-6 levels differed
from baseline at concentrations of O/P ≥2×. (B) Mice were exposed to a
single aerosolized 8× dose of O/P, then sacriﬁced at the indicated times, and
the IL-6 concentration in serum was measured. The level of IL-6 differed
signiﬁcantly from baseline only at 48 h. (C) Mice were exposed to increasing
concentrations of O/P as indicated, then sacriﬁced after 4 h to measure SAA1
transcript levels in their livers. Levels of SAA1 transcripts differed from
baseline at concentrations of O/P ≥2×. (D) Mice were exposed to a single
aerosolized 8× dose of O/P (black circles, Y-axis on the right), then sacriﬁced
at the indicated times to measure SAA1 transcript levels in their livers. For
comparison, mice were injected intravenously (gray squares,Y-axis on the left)
with an amount of O/P estimated to be 100-fold the amount deposited in the
lungs after a single aerosolized 8× dose. Levels of SAA1 transcripts differed
from baseline at 24 and 48 h. (n = 4–5 for all experiments).
suggest that aerosolized O/P causes only minimal changes in
physiology.
ANIMAL BEHAVIOR AFTER O/P EXPOSURE
Since mouse behavioral models can provide sensitive indica-
tors of inﬂammation or distress, we evaluated the impact of
aerosolized O/P using multiple well-established models. There
was no loss of preference for lightly sweetened water (1% sucrose)
over unsweetened water in mice treated with any concentration of
aerosolized O/P in comparison to mice treated with aerosolized
water (Figure 6A). As a positive control, mice that received 50 μg
of endotoxin by i.p. injection almost entirely lost their prefer-
ence for sweetened water during the ﬁrst 24 h after injection
(Figure 6A). There was an approximately 30% decrease in total
water consumption in all groups of mice during the ﬁrst 24 h
after aerosol exposure with no difference between those exposed
to vehicle alone compared to those exposed to O/P (not shown).
Decreased food consumption, social interaction, and locomotion
(quadrant entry and rears) are additional indicators of distress in
mice. Neither 1× nor 8× aerosolized O/P caused any decrease
in food consumption (Figure 6B), social interaction (Figure 6C),
or locomotion (Figures 6D,E) as compared to aerosolized water,
though 20 μg of i.p. endotoxin caused a signiﬁcant decrease
in each of these measures at early time points. Together,
these results suggest that aerosolized O/P is well tolerated by
mice.
DISCUSSION
We have previously identiﬁed a combination of TLR ligands
that effectively induces resistance to microbial infection (Duggan
et al., 2011; Evans et al., 2011; Tuvim et al., 2012; Cleaver et al.,
2014). While it is formally possible to separate host responses
that directly mediate pathogen killing (e.g., expression of antimi-
crobial peptides and generation of reactive oxygen species) from
inﬂammatory responses that recruit leukocytes (e.g., expression
of chemokines and generation of eicosanoids), the stimulation
of innate immunity generally induces resistance and inﬂamma-
tion together (Evans et al., 2010b). Therefore, pragmatically at
this point in time, therapeutic stimulation of innate immu-
nity to treat infection depends upon whether accompanying
inﬂammatory responses are acceptable. Here we have analyzed
in mice, the species in which we have done most of our work
on inducible resistance, the safety and tolerability of treatment
with O/P.
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FIGURE 7 | Physiologic responses to aerosolized O/P. (A,B)The weight
(A) and temperature (B) of mice exposed to increasing concentrations of
O/P as indicated by the various colored lines was recorded at the indicated
times. Asterisks indicate differences in comparison to mice treated with
vehicle alone. (C)The respiratory rate of mice treated with aerosolized
vehicle alone (water, black circles), or 1× (gray squares) or 8× (gray
triangles) O/P. There were no differences in comparison to mice treated
with vehicle alone. (n = 4–5 for all experiments).
LUNG INFLAMMATION
The lungs are the site of delivery of aerosolized O/P, so should be
the site of most intense inﬂammation. At therapeutic doses, O/P
caused an acute inﬂammatory response characterized by a rise
in inﬂammatory cytokines and neutrophils in lung lavage ﬂuid,
but with minimal tissue inﬁltration by leukocytes histopathologi-
cally (Figure 1). The cytokines in lavage ﬂuid returned to baseline
within 2 days and the neutrophils within 4 days. The presence of
lavage ﬂuid neutrophils was paralleled by a small transient increase
in lung permeability (Figure 5), which did not result in respira-
tory distress or a rise in respiratory rate (Figure 7C). The transient
rise in lavage ﬂuid neutrophils contrasts with an initial fall in
macrophages, possibly due to their mobilization to local lymph
nodes or increased adhesion to alveolar walls (Geissmann et al.,
2010), followed by a late rise in macrophages that is probably part
of the process of clearance of inﬂammation (Figure 1B).
The moderate intensity of lung inﬂammation seen here could
be expected from the mild inﬂammation we observed with
aerosolization of a TLR9 agonist alone (Duggan et al., 2011) and
others observed with intratracheal instillation of TLR9 agonists
(Schwartz et al., 1997; Duechs et al., 2011) in mice, combined with
the moderate inﬂammation we observed with aerosolization of
a TLR2 agonist alone (Duggan et al., 2011) and others observed
with intratracheal instillation of a TLR2 agonist (Schwartz et al.,
1997; Duechs et al., 2011). However these ﬁndings stand in con-
trast to the severe lung inﬂammation reported with intranasal
administration to mice of a TLR9 agonist (Campbell et al., 2009).
The agonist used in that study was a Class B ODN with higher
activity toward rodents than primates (Campbell et al., 2009),
whereas we used a Class C ODN with similar activity toward
rodents and primates, but Duechs et al. (2011) also used a Class
B ODN with higher activity toward rodents than primates with-
out causing severe inﬂammation. Another possible explanation
of the discrepancy is the higher dose used by Campbell et al.
(2009; 5 mg/kg, yielding 150 μg for a 30 g mouse, and esti-
mated lung deposition of 50% for intranasal instillation = 75μg),
compared to the low dose in our study (8.58 μg/ml in nebu-
lizer × 4 ml × 0.1% deposition = 34 ng). However, the dose
used by Duechs et al. (2011) (1 mg/kg, yielding 30 μg for a 30 g
mouse, and estimated lung deposition of 100% for intratracheal
instillation = 30 μg) was only slightly lower than the dose used by
Campbell et al. (2009) yet caused only mild inﬂammation. Thus,
the cause of the discrepancy between the severe lung inﬂamma-
tion in response to a TLR9 agonist reported by Campbell et al.
(2009) and themild inﬂammation reported by us and others is not
apparent.
An interesting feature of lung inﬂammation in response to
aerosolized O/P was its self-limited nature. The rise in lavage
cytokines andneutrophilswas dose-dependent up to the therapeu-
tic dose, but plateaued at higher doses (Figure 2). This suggests
that TLR2/6 and TLR9 receptors in the airways are saturated at
this dose of ligands, or that downstream signaling pathways lead-
ing to both antimicrobial and cytokine responses are maximally
activated. Even more striking was the degree of tachyphylaxis with
repetitive dosing, such that lavage neutrophils barely rose at all
after six doses and cytokines rose only a fraction as high as after a
single dose (Figures 1C,D). These ﬁndings are consistent with our
earlier ﬁnding of tachyphylaxis of lung inﬂammation (Moghad-
dam et al., 2008), though not of antimicrobial resistance (Tuvim
et al., 2009; Evans et al., 2010a), induced by repetitive exposure to
an aerosolized bacterial lysate. Others have similarly found tachy-
phylaxis of inﬂammation but not of antimicrobial responses in
response to a TLR agonist in vitro (Foster et al., 2007). Together,
these ﬁndings indicate that lung inﬂammation from aerosolized
O/P is limited in severity, in duration, and in response to repetitive
exposure.
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SYSTEMIC RESPONSES
There was a small rise in serum IL-6 after aerosolized O/P
(Figures 6A,B), but no detectable rise in TNF or CXCL2, suggest-
ing that inﬂammation is mostly contained within the lungs. This
is similar to our prior ﬁnding of a minimal rise in serum cytokines
after exposure to an aerosolized bacterial lysate (Tuvim et al.,
2009), and consistent with the lack of systemic antimicrobial resis-
tance after stimulation of lung innate immunity (Clement et al.,
2008). Even the expression of SAA1 transcripts in the liver, a highly
sensitive indicator of systemic inﬂammation (Quinton et al., 2009)
and the most highly upregulated gene in the lungs of mice
treated with O/P (Evans et al., 2010a), rose only minimally after
aerosolized O/P (Figures 6C,D). This small degree of systemic
inﬂammation is more likely due to the relay of local inﬂammatory
responses from the lungs rather than translocation of aerosolized
O/P into the systemic circulation because intravenous injection of
quantities of O/P many times greater than those calculated to be
deposited in the lungs after aerosolization resulted in only modest
rises in hepatic SAA1 transcripts (Figure 6D) and lung permeabil-
ity (Figure 5C). The mild systemic inﬂammation after aerosolized
O/P was not reﬂected in changes in the respiratory rate or core
temperature of mice (Figures 7B,C), though there was a small
transient reduction in weight (Figure 7A) and water consump-
tion (not shown) in mice treated with an 8× dose. Behavioral
FIGURE 8 | Behavioral response to aerosolized O/P. (A) Mice were
exposed to increasing concentrations of aerosolized O/P (symbols with solid
lines) or to saline solution (SAL) or lipopolysaccharide (LPS) given by
intraperitoneal (i.p.) injection (symbols with dashed lines). For the next 4 days,
their preference for lightly sweetened water (1%) over unsweetened water
was measured. Statistical analysis was not performed because data points
represent measurements from a single cage (n = 5). (B–E) Mice were
exposed to 1× or 8× doses of aerosolized O/P and compared to mice
exposed to aerosolized vehicle (water) or injected i.p. with LPS. The rate of
food disappearance (B), seconds per 5 min spent in social interaction with a
novel untreated age and sex matched mouse introduced into the cage (C),
and the number of quadrant entries (D) and rears (E) per 5 min of mice
introduced into novel cages were measured for the next 24 h. Asterisks
indicate differences in comparison to mice treated with vehicle alone (n = 8).
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models of stress showed no differences between mice treated with
vehicle and those treated with aerosolized O/P, even though those
models were sensitive to low doses of intravenous lipopolysac-
charide (LPS; Figure 8). These ﬁndings of minimal systemic
inﬂammation stand in contrast to the severe macrophage activa-
tion syndromewith cytokine storm, lymphoid follicle destruction,
splenomegaly and hepatitis that occurred after repetitive i.p. injec-
tion of 50 μg of a Class B ODN in mice (Heikenwalder et al.,
2004; Behrens et al., 2011; Canna et al., 2013). It appears that
the activation of innate immunity at mucosal surfaces differs
fundamentally from its activation within the body in the inten-
sity of systemic inﬂammation evoked since we ﬁnd substantial
inﬂammation within the lung lumen but minimal transmission
systemically.
BIOMARKERS
Pharmacodynamic measures of the activity of aerosolized O/P
could be important in determining therapeutic dose levels in clin-
ical trials. The close correlation between the rising portion of the
dose–response curves for antimicrobial efﬁcacy and lung lavage
cytokines in mice (Figure 2) suggests that induced sputum or
bronchoalveolar lavage ﬂuid might be sampled in human subjects
for this purpose. The synergistic increase in lavage ﬂuid cytokine
levels when ODN and Pam2CSK4 are administered together com-
pared to their levels when each agonist is administered alone
(Figure 2C) mirrors the synergistic induction of antimicrobial
resistance and neutrophil recruitment by these ligands (Dug-
gan et al., 2011; Tuvim et al., 2012; Cleaver et al., 2014), further
validating the utility of these cytokines as biomarkers of phar-
macodynamic activity. The preservation of resistance (Figure 4A
andDuggan et al., 2011; Tuvim et al., 2012; Cleaver et al., 2014) and
cytokine (Figure 4B) responses inmyeloablatedmice suggests that
clinical studies in patients with hematologic malignancies under-
going myeloablative chemotherapy could also be guided by lung
lining ﬂuid cytokine biomarkers. The rise in serum IL-6 in mice
(Figure 6) suggests that serum cytokine measurements in human
subjectsmight also be useful.Whereas the dose–response relation-
ship between antimicrobial efﬁcacy and cytokine levels is close,
some cytokines rise slightly faster than the induction of antimi-
crobial resistance [CXCL2 and TNF in Figure 1A, compared to
the kinetics of resistance in Clement et al. (2008) Figure 1], and
some rise slower (IL-6 in Figure 1A). More importantly, all three
cytokines decline to baseline by 24–48 h while antimicrobial resis-
tance remains high several days longer (Clement et al., 2008; Tuvim
et al., 2009, 2012; Evans et al., 2010a; Duggan et al., 2011). Thus,
cytokine measurement should be useful for dose ﬁnding but not
for the assessing the kinetics of activity. Measurement of a key
antimicrobial activity would serve as a better kinetic biomarker,
but the essential effectors of inducible epithelial resistance are not
yet known (Evans et al., 2010b, 2011; Cleaver et al., 2014).
CONCLUSION
Exposure of mice to an aerosolized combination of TLR2/6
and TLR9 ligands induces transient and self-limited neutrophilic
inﬂammationwithin the lungs that is associated withminimal sys-
temic inﬂammation or physiologic and behavioral responses. The
dose-dependent rise in cytokines in lung lining ﬂuid and serum
could serve as biomarkers of pharmacodynamic effects for dose-
ﬁnding in clinical trials. Together, these ﬁndings suggest that itmay
be feasible touse aerosolizedTLR ligands to treat immunocompro-
mised subjects to prevent opportunistic lung infections or normal
subjects to attenuate lung infections with virulent pathogens.
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